A whole-genome and transcriptome analysis platform for cancer that provides comprehensive tumor profiling beyond standard gene panels.
Isabl GxT is a genomic diagnostics platform that analyzes 100% of a cancer patient's tumor genome and transcriptome, uncovering all relevant cancer-associated mutations rather than only those detected by limited gene panels. The platform holds FDA Breakthrough Device Designation and is developed by a team from Memorial Sloan Kettering, Harvard, and Weill Cornell Medicine. It enables broader biomarker discovery and improved diagnostic clarity for cancer patients. Isabl GxT is a product of Isabl.